Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the bacteria-based cancer drug developer.
T3 Pharma, a Switzerland-based developer of immuno-oncology treatments, closed more than CHF25m ($26.8m) in funding yesterday from investors including pharmaceutical firm Boehringer Ingelheim.
The corporate’s Boehringer Ingelheim Venture Fund (BIVF) joined Reference Capital, Wille Finance and undisclosed private investors in what was the third funding round to be completed by the company.
Founded in 2015 as a University of Basel spinout, T3 is using live bacteria to create cancer drugs designed to work by triggering the body’s immune response. It…
